NICE does not recommend Stivarga as a treatment for liver cancer.- Bayer Healthcare.
The National Institute for Health and Care Excellence (NICE) does not recommend Stivarga (regorafenib) from Bayer HealthCare, as a treatment for advanced, unresectable liver cancer (hepatocellular carcinoma) for patients who cannot tolerate Nexavar (sorafenib). NICE found that the survival benefit is unclear and that those who are intolerant to sorafenib, those who have more severe liver disease and those who have a poorer performance status, were not included in the trial. NICE found that the drug was not cost effective. The drug is also not recommended through the Cancer Drugs Fund.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.